
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
An earlier version of this article was published by NeurologyLive®. The investigational agent gefurulimab (AstraZeneca), a subcutaneous complement C5 inhibitor administered once weekly, has produced positive data in the phase 3 PREVAIL study (NCT05556096), …